

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Keymed Biosciences Inc.**  
**康諾亞生物醫藥科技有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2162)**

**VOLUNTARY ANNOUNCEMENT**  
**INCLUSION OF THE COMPANY AS AN ELIGIBLE STOCK OF THE**  
**SHENZHEN-HONG KONG STOCK CONNECT**

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest development of the Company.

The Company is pleased to announce that the shares of the Company have been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect with effect from March 7, 2022, pursuant to the Announcement on Adjustment of the Stock List of the Shenzhen-Hong Kong Stock Connect issued by the Shenzhen Stock Exchange on March 7, 2022.

The Company believes the inclusion of the Company in the trading mechanism of the Shenzhen-Hong Kong Stock Connect programme will allow the Company to access a broader investor base in Mainland China and increase the trading liquidity of the shares of the Company, which would result in realization of the value of investment in the Company and further enhancement of the Company’s brand awareness.

The Company would like to thank the shareholders and investors of the Company for their continued support. The Company will continue to strive to develop its business and create value for its shareholders.

By order of the Board of Directors  
**Keymed Biosciences Inc.**  
**Dr. Bo CHEN**  
*Chairman*

Hong Kong, March 7, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Dong LYU, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.*